• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Primary Care

Diagnosis and Management of Atrial Fibrillation

image_pdfFavoriteLoadingFavorite

SUMMARY:

Atrial fibrillation, the most common cardiac arrhythmia, increases stroke risk and can exacerbate underlying heart disease. The 2014 ACC/AHA/HRS Guideline for the Management of Patients with Atrial Fibrillation offers a comprehensive approach to treating this condition. A focused update released in 2019 includes new evidence in support of novel drugs and devices to prevent thromboembolism, as well as other clinical considerations. Of note, these recommendations apply to atrial fibrillation (AF) and atrial flutter, regardless of the pattern of arrhythmia (i.e. paroxysmal, persistent, or permanent).

  • Diagnosis and Workup
  • Treatment Highlights
  • Risk stratification
  • Anticoagulation
  • Alternatives to Anticoagulation
  • Rate Control
  • Rhythm Control

Diagnosis and Workup

  • Diagnosed by EKG or cardiac monitoring: Characteristic irregular rhythm without discrete p-waves
  • Workup at time of diagnosis should include
    • TTE | Thyroid function tests | CBC | Renal function and electrolytes | LFTs | CXR (if suspicion for heart failure or pulmonary disease) | Sleep study (if suspicion for sleep apnea)
  • Outpatient management appropriate for hemodynamically stable patients without evidence of severe volume overload or acute coronary syndrome

Note: Routine screening for AF in the general population is not currently recommended by the USPSTF | The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AF (I statement)

Treatment Highlights

  • Mainstays of treatment for most patients are anticoagulation (warfarin vs. NOAC) and rate control (typically beta blocker or nondihydropyridine calcium channel blocker)
  • For some patients, attempted cardioversion to sinus rhythm may be preferred initially
  • Invasive procedures to ablate AF or occlude the LAA are appropriate for select patients

KEY POINTS:

  • Valvular vs. non-valvular AF
    • Valvular: AF associated with moderate to severe mitral stenosis or mechanical heart valve
    • Non-valvular: All other AF (much more common)

Risk stratification

  • CHA2DS2-VASc:  Estimates annual stroke risk for non-valvular AF, based on various demographic and comorbid factors
    • Anticoagulation is recommended for score ≥2 in men, ≥3 in women
    • Anticoagulation “may be considered” for score 1 in men, 2 in women; aspirin is also an option
  • Stroke risk can be weighed against bleeding risk using clinical calculators such as HAS-BLED
    • However per ACC/AHA “their clinical utility is insufficient for use as evidence”
    • Higher bleeding risk may warrant closer monitoring of anticoagulated patients, but should not necessarily preclude anticoagulation

Anticoagulation

Choosing an anticoagulant

  • Goal is to prevent thromboembolic events
  • Decision to start anticoagulation should always involve discussion of risks vs benefits

Medications

  • Warfarin
    • Indicated for all valvular AF
    • Goal INR 2-3
  • Novel oral anticoagulants (NOACs) recommended over warfarin for non-valvular AF in absence of contraindications
    • Dabigatran (Pradaxa) | Rivaroxaban (Xarelto) | Apixaban (Eliquis) | Edoxaban (Savaysa)
    • All either superior or non-inferior to warfarin | Do not require INR monitoring | Have lower risk of major bleeding
    • All have reduced dose options for CKD
  • ESRD
    • Use warfarin or apixaban (limited data to support this)
  • Bridging
    • For patients with mechanical heart valves undergoing surgery or other invasive procedure, bridge with unfractionated or low molecular weight heparin to provide uninterrupted anticoagulation
    • For all others, a brief interruption of therapy without bridging is considered safe
  • Anticoagulation with antiplatelet therapy
    • Patients with AF and recent coronary stenting who are on triple therapy (oral anticoagulant + aspirin + P2Y12 inhibitor) may be narrowed to double therapy (warfarin, dabigatran, or rivaroxaban + P2Y12 inhibitor) to reduce bleeding risk

Dosing

  • Apixaban (Eliquis)
    • Usual dose: 5 mg twice a day
    • Adjusted dose: 2.5 mg twice a day if ≥2 of the following
      • Age: ≥80 years
      • Body weight: ≤60 kg
      • Serum creatinine: ≥1.5 mg/dL

Note:  Caution with use of apixaban and the following 

  • Other medications that can interfere with hemostasis: May increase risk of bleeding
    • Aspirin and antiplatelet agents | Other anticoagulants | Heparin | Thrombolytic agents | SSRIs | SNRIs | NSAIDs (chronic use) | Fibrinolytics
  • Combined P-gp and strong CYP3A4 inhibitors
    • Ketoconazole | Itraconazole | Ritonavir
    • Reduce dose by 50% in usual dosing regimen and do not use with 2.5 mg reduced dose | Dose does not need to be altered with clarithromycin
  • Combined P-gp and strong CYP3A4 inducers: Avoid concomitant use
    • Rifampin | Carbamazepine | Phenytoin | St. John’s wort

  • Dabigatran (Pradaxa)
    • CrCl >30 mL/min: 150 mg orally, twice daily
    • CrCl 15 to 30 mL/min: 75 mg orally, twice daily

Note: Exercise caution with use of dabigatran and the following

  • P-gp inducers rifampin: Avoid coadministration
  • P-gp inhibitors in patients with CrCl 30-50 mL/min: Reduce dose or avoid
  • P-gp inhibitors in patients with CrCl <30 mL/min: Not recommended

  • Rivaroxaban (Xarelto)
    • 15 or 20 mg, once daily with food

Note: Exercise caution with use of rivaroxaban and the following

  • Avoid combined P-gp and strong CYP3A inhibitors and inducers
  • Anticoagulants: Avoid concomitant use
  • Renal impairment: Avoid or adjust dose
  • Hepatic impairment: Avoid use in Child-Pugh B and C hepatic impairment or with any degree of hepatic disease associated with coagulopathy

Alternatives to Anticoagulation

  • Since thromboemboli tend to develop in the left atrial appendage (LAA), non-pharmacologic strategies for minimizing stroke risk involve occluding or removing the LAA
    • Percutaneous LAA occlusion (Watchman device): For patients with a contraindication to long-term anticoagulation (however, must be able to receive periprocedural anticoagulation)
    • Surgical LAA occlusion/excision: Only for patients already undergoing cardiac surgery for another indication

Rate Control

  • Goal: To reduce symptoms, improve intra-cardiac hemodynamics and perfusion, and prevent tachycardia-induced cardiomyopathy
  • Choosing a rate control strategy
    • Beta blockers (metoprolol, carvedilol, atenolol) or nondihydropyridine calcium channel blockers (diltiazem, verapamil) are first-line
    • Avoid CCBs in heart failure with reduced EF
    • Second-line options include digoxin (possibly associated with increased mortality) and amiodarone (not for long-term use due to toxicities)
  • Strict (<80 bpm) vs. lenient (<110 bpm) rate control
    • Lenient approach acceptable as long as patient is asymptomatic and with preserved EF

Rhythm Control

  • Not superior to rate control and associated with increase in hospitalizations
  • May be indicated for new-onset AF, persistent symptoms, difficulty achieving rate control, young age, or tachycardia-induced cardiomyopathy
    • These approaches generally require expert consultation
  • Electrical cardioversion
    • In non-emergent setting, requires anticoagulation three weeks pre- and four weeks post-procedure (if duration of AF >48 hours or unknown)
    • Often preceded by TEE to exclude LA thrombus
  • Maintaining sinus rhythm
    • Typically achieved with antiarrhythmics (e.g. amiodarone, dofetilide, flecainide)
    • Caution: These drugs have significant side effects and toxicities
  • Catheter ablation
    • For symptomatic paroxysmal AF not responding to antiarrhythmic therapy

Learn More – Primary Sources:

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

AAFP: Diagnosis and Treatment of Atrial Fibrillation

Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement | Atrial Fibrillation

NOAC trials: RE-LY (dabigatran)

ROCKET-AF (rivaroxaban)

ARISTOTLE (apixaban)

CHA2DS2-VASc Calculator

HAS-BLED Calculator

Get Guideline Notifications Direct to Your Phone

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Primary Care Posts
Next >

Related ObG Topics:

Do More Pregnancies Increase Risk of Atrial Fibrillation?
The Relationship between Exercise and Heart Disease – Does Genetics Matter?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site